profit from every $100 of sales.
$0$100
Greenwich LifeSciences
$14.94-2.23% today
+82.2% in 1 year
1-year low $7.851-year high $33.56
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Greenwich LifeSciences sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$19.4 million of profit last year.
SalesProfit
Greenwich LifeSciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Greenwich LifeSciences | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Greenwich LifeSciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -8 | -9 | -18 | -19 | |
| -8 | -9 | -18 | -19 | |
| -8 | -9 | -17 | -19 | |
| -0.61 | -0.69 | -1.34 | -1.43 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 13 | 7 | 4 | 6 |
| Cash | 13 | 7 | 4 | 6 |
| Total debt | – | – | – | – |
| Total liabilities | 0 | 0 | 3 | 6 |
| 13 | 7 | 1 | 0 | |
| 13 | 13 | 13 | 14 | |
| -48.1% | -110.0% | -1,533.5% | -4,349.7% | |
| -59.2% | -132.7% | -1,916.5% | -5,480.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -6 | -6 | -7 | -10 | |
| – | – | – | – | |
| -6 | -6 | -7 | -10 | |
| Dividends paid | – | – | – | – |
| 8 | 0 | – | – | |
| 2 | 2 | 7 | 7 |
Valuation
- –
- –
- –
- 164.3×
- –
- –
- –
- -3.3%
- -7.2%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -896.4%
- -167.7%
- -1,042.8%
- -511.6%
- -896.4%
- –
Growth
- –
- –
- −12.2%
- –
- +0.6%
Financial health
- -0.2×
- 0.00
- 0.0%
- –
- 2.35
- 2.35
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 20%of 883
Bottom 22%of 987
What analysts expect
- Average price target
- $50.00
- Range
- $50.00 – $50.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Nov 14, 2025 | -0.30 | -0.30 | +0.0% |
| Aug 14, 2025 | -0.30 | -0.24 | −25.0% |
| May 20, 2025 | -0.25 | -0.24 | −4.2% |
| Apr 15, 2025 | -0.61 | -0.21 | −190.5% |
| Nov 14, 2024 | -0.20 | -0.21 | +4.8% |
| Aug 14, 2024 | -0.20 | -0.20 | +0.0% |
| May 20, 2024 | -0.19 | -0.20 | +5.0% |
| Apr 15, 2024 | -0.21 | -0.20 | −5.0% |
News
‘Sex and the City’ star Chris Noth is selling his ‘breathtaking’ Greenwich Village apartment for $1.5 millionMarketWatch · Sep 28, 2026The newest story we have is from Sep 28, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
21No pass
Benjamin Graham
52No pass
Philip Fisher
34No pass
Peter Lynch
60Pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
21No pass
Questions about Greenwich LifeSciences
Is Greenwich LifeSciences a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Greenwich LifeSciences AI analysis
What does Greenwich LifeSciences do?
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. It is in Biotechnology.
Does Greenwich LifeSciences pay a dividend?
No. Greenwich LifeSciences does not pay a dividend at the moment.
Is Greenwich LifeSciences stock halal?
Yes. Greenwich LifeSciences passes our halal screen: its business is permitted and its debt is 0% of its market value, under the 30% limit. How we check
How has Greenwich LifeSciences stock done over the past year?
Up 82.2% over the past twelve months, to $14.94. It traded between $7.85 and $33.56 and is 55.5% below its high.
Who are Greenwich LifeSciences's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Greenwich LifeSciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.